Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro

Li, X.-n.; Bu, Hengtao; Ma, Xingxin; Lu, Shan; Cui, Yugui; Sun, Jiantong

doi:10.1055/s-0042-112368

Cited by 13 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both exenatide and liraglutide inhibited cell proliferation and increased apoptotic cell death in prostate cancer cells in a dose-dependent manner via an increase in the ratio of pro-apoptotic Bax/anti-apoptotic Bcl-2 and activation of the p38 MAPK-dependent cell death pathway [ 36 ]. Exenatide treatment reportedly exerted antiproliferative effects in the prostate cancer cell lines (LNCap, PC3, and DU14) and attenuated the growth of LNCap-derived xenografts in athymic mice [ 37 ].…”

Section: Possible Anti-cancer Effects Of Trzdmentioning

confidence: 99%

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

et al. 2022

View full text Add to dashboard Cite

It is a well-accepted fact that obesity and diabetes increase the risk of incidence of different cancers and their progression, leading to a decrease in the quality of life among affected cancer patients. In addition to decreasing the risk of cancers, maintaining a healthy body mass index (BMI)/body weight and/or blood glucose levels within the normal range critically impacts the response to anti-cancer therapy among affected individuals. A cancer patient managing their body weight and maintaining blood glucose control responds better to anti-cancer therapy than obese individuals and those whose blood glucose levels remain higher than normal during therapeutic intervention. In some cases, anti-diabetic/glucose-lowering drugs, some of which are also used to promote weight loss, were found to possess anti-cancer potential themselves and/or support anti-cancer therapy when used to treat such patients. On the other hand, certain glucose-lowering drugs promoted the cancer phenotype and risked cancer progression when used for treatment. Tirzepatide (TRZD), the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide/gastric inhibitory peptide (GIP) agonist, has recently gained interest as a promising injectable drug for the treatment of type 2 diabetes and was approved by the FDA after successful clinical trials (SURPASS 1/2/3/4 and 5, NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503). In addition, the reports from the SURMOUNT-1 clinical trial (NCT04184622) support the use of TRZD as an anti-obesity drug. In the current review article, we examine the possibility and molecular mechanisms of how TRZD intervention could benefit cancer therapeutics or increase the risk of cancer progression when used as an anti-diabetic drug in diabetic patients.

show abstract

Section: Possible Anti-cancer Effects Of Trzdmentioning

confidence: 99%

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…EXE and LIRA both inhibited the proliferation of endometrial carcinoma cells, through the AMPK signaling pathway [ 140 , 141 ]. The antiproliferative activity of EXE and LIRA has been reported on human prostate and hepatocellular carcinoma cells [ 142 , 143 ]. Thus, there is abundancy of preclinical data about the antitumorigenic effect of GLP-1 RAs.…”

Section: Cancermentioning

confidence: 99%

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity

et al. 2022

View full text Add to dashboard Cite

Background: Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RA’s) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However their effect on the complications of obesity have not been very well recognized. This review aims to analyze the effects of GLP-RA’s on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA) and central nervous system problems. Summary: Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review has covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated, it is clear that the effects are not solely due to weight loss, but some pleiotropic effects like decreased inflammation, oxidative stress and fibrosis also play role in some of the complications. Key messages: Treating obesity is not only enabling weight loss but ameliorating complications related with obesity. Thus any anti-obesity medication has to have some favorable effects on the complications. As far as the GLP-RA’s analogs are concerned, there seem to be improvement in many of the complications regardless of the weight loss effect of these medications.

show abstract

“…Liraglutide attenuates prostate cancer growth through regulation of the p38 pathway by binding with the GLP-1 receptor in vitro. 50 Forced expression of GLP-1 receptor attenuates prostate cancer cell proliferation by inhibiting cell cycle progression in vitro and in vivo. 51 A recent study also showed that an anticancer drug and liraglutide decreased the viability of prostate cancer cells (LNCaP) synergistically.…”

Section: Prostate Cancermentioning

confidence: 99%

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes

Seo

2021

Journal of Obesity & Metabolic Syndrome

View full text Add to dashboard Cite

Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indication has been expanded. Body mass index criteria for patients prescribed the drug in the real world tend to be applied less rigorously, which may increase the number of adverse reactions due to over-prescription. Liraglutide treatment was found effective and safe in some studies, while others have warned about its risks. Therefore, this review summarizes the current data available on side effects associated with liraglutide.

show abstract

Glucagon-like Peptide-1 Analogues Inhibit Proliferation and Increase Apoptosis of Human Prostate Cancer Cells in vitro

Cited by 13 publications

References 14 publications

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes

Contact Info

Product

Resources

About